

**COMPENSATION RESULTS BY NIOSH-IREP CANCER MODEL**  
**BASED ON CLAIMS WITH DR APPROVED AND SUBMITTED TO DOL THROUGH Sep. 21, 2012 (31,467 CLAIMS)**

Rank by Compensation Rate	NIOSH-IREP CANCER MODEL (ICD-9 Code)	Compensated (PC ≥ 50%)		Not Compensated (PC < 50%)		Total Claims	
		N	%	N	%	N	%
1	Lung (162)	2940	65	1581	35	4521	20.335
2	Chronic Myeloid Leukemia (205.1)	48	53.3	42	46.7	90	0.405
3	Non-melanoma skin-Basal Cell (173)	947	52.8	846	47.2	1793	8.065
4	Acute Lymphocytic Leukemia (204.0)	41	50	41	50	82	0.369
5	Liver (155.0)	75	43.1	99	56.9	174	0.783
6	Acute Myeloid Leukemia (205.0)	73	37.4	122	62.6	195	0.877
7	Lymphoma & multiple myeloma (200-203)	626	36.9	1071	63.1	1697	7.633
8	Malignant melanoma (172)	226	35.4	412	64.6	638	2.87
9	Other respiratory (160,161,163-165)	186	30.4	426	69.6	612	2.753
10	Leukemia, excl. CLL (204-208,excl. 204.1)	42	30.2	97	69.8	139	0.625
11	Oral Cavity and Pharynx (140-149)	98	22.1	346	77.9	444	1.997
12	Bone (170)	41	18.3	183	81.7	224	1.008
13	Thyroid (193)	52	16.5	264	83.5	316	1.421
14	Gallbladder (155.1,156)	17	15.2	95	84.8	112	0.504
15	Eye (190)	5	9.8	46	90.2	51	0.229
16	Stomach (151)	49	9.3	479	90.7	528	2.375
17	Colon (153)	91	7.5	1116	92.5	1207	5.429
18	Urinary organs, excluding bladder (189)	41	6.8	559	93.2	600	2.699
19	Bladder (188)	41	6.7	570	93.3	611	2.748
20	Other endocrine glands (194)	1	3.7	26	96.3	27	0.121
21	All Male Genitalia (185-187)	136	3.2	4177	96.8	4313	19.399
22	Esophagus (150)	4	2.9	136	97.1	140	0.63
23	Connective tissue (171)	4	2.8	137	97.2	141	0.634
24	All digestive (150-159)	3	2.7	108	97.3	111	0.499
25	Other and ill-defined sites (195)	1	1.9	51	98.1	52	0.234
26	Breast (174-175)	16	1.8	897	98.2	913	4.107
27	Non-melanoma skin-Squamous Cell (173)	11	1.7	622	98.3	633	2.847
28	Pancreas (157)	5	0.9	575	99.1	580	2.609
29	Rectum (154)	3	0.6	516	99.4	519	2.334
30	Nervous system (191-192)	1	0.2	414	99.8	415	1.867
31	Female Genitalia, excl. ovary (179-	0	0	242	100	242	1.088
32	Ovary (183)	0	0	113	100	113	0.508
<b>Subtotal for Claims with a Single Primary Cancer</b>		<b>5824</b>	<b>26.2</b>	<b>16409</b>	<b>73.8</b>	<b>22233</b>	<b>70.7</b>
<b>Subtotal for Claims with Multiple Primary Cancers</b>		<b>3248</b>	<b>35.2</b>	<b>5986</b>	<b>64.8</b>	<b>9234</b>	<b>29.3</b>
<b>GRAND TOTAL (ALL CLAIMS)</b>		<b>9072</b>	<b>28.8</b>	<b>22395</b>	<b>71.2</b>	<b>31467</b>	<b>100.0</b>



The data presented on this page:  
 May not be predictive of future results;  
 Reflect claims with only one reported primary cancer (unless otherwise noted); and,  
 Are in some cases based on a small number of cases.



The data present on this page are indicative of compensation rates for claims that have gone through dose reconstruction and do not include claims that have been awarded compensation through the Special Exposure Cohort (SEC) process. Thus, overall compensation rates for the 22 cancers that are included in the SEC may be higher.